NCT04331899View on ClinicalTrials.gov

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 25, 2020

Primary Completion Date

August 14, 2020

Study Completion Date

May 6, 2021

Conditions
COVID-19
Interventions
DRUG

Peginterferon Lambda-1a

Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care

OTHER

Placebo

Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04331899 - Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 | Biotech Hunter | Biotech Hunter